{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:27:49Z","timestamp":1778642869020,"version":"3.51.4"},"reference-count":9,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.1001\/jamaophthalmol.2019.1519","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T11:30:54Z","timestamp":1559820654000},"page":"932","source":"Crossref","is-referenced-by-count":6,"title":["Patient-Reported Visual Function Outcomes After Anti\u2013Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion"],"prefix":"10.1001","volume":"137","author":[{"given":"Ingrid U.","family":"Scott","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Penn State College of Medicine, Hershey, Pennsylvania"},{"name":"Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.","family":"VanVeldhuisen","sequence":"additional","affiliation":[{"name":"The Emmes Corporation, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franca","family":"Barton","sequence":"additional","affiliation":[{"name":"The Emmes Corporation, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal L.","family":"Oden","sequence":"additional","affiliation":[{"name":"The Emmes Corporation, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Ip","sequence":"additional","affiliation":[{"name":"Doheny Eye Institute, University of California, Los Angeles"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Blodi","sequence":"additional","affiliation":[{"name":"University of Wisconsin Fundus Photograph Reading Center, Madison"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Worrall","sequence":"additional","affiliation":[{"name":"Retina Centers, PC, Tucson, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary E.","family":"Fish","sequence":"additional","affiliation":[{"name":"Texas Retina Associates, Dallas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Study of Comparative Treatments for Retinal Vein Occlusion 2 Investigator Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"20","key":"ebr190008r1","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1001\/jama.2017.4568","article-title":"Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial.","volume":"317","author":"Scott","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"ebr190008r2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/archopht.116.2.227","article-title":"Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons.","volume":"116","author":"Mangione","year":"1998","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"ebr190008r3","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1001\/archopht.116.11.1496","article-title":"Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ).","volume":"116","author":"Mangione","year":"1998","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"ebr190008r4","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute Visual Function Questionnaire.","volume":"119","author":"Mangione","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"ebr190008r5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ophtha.2016.09.038","article-title":"SCORE2 report 2: study design and baseline characteristics.","volume":"124","author":"Scott","year":"2017","journal-title":"Ophthalmology"},{"issue":"20","key":"ebr190008r6","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"ebr190008r8","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","article-title":"Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials.","volume":"119","author":"Varma","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"ebr190008r9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/bjophthalmol-2012-301504","article-title":"VEGF Trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study.","volume":"97","author":"Holz","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"ebr190008r7","volume-title":"Multiple Comparisons and Multiple Tests Using the SAS System","author":"Westfall","year":"1999"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/article-pdf\/137\/8\/932\/17773711\/jamaophthalmology_scott_2019_br_190008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T11:01:45Z","timestamp":1565262105000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2734817"}},"subtitle":["Preplanned Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.1519","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,1]]}}}